- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
21 result(s) found for: Lung parenchyma.
Displaying page 1 of 2.
EudraCT Number: 2017-002508-29 | Sponsor Protocol Number: CEFTAROPROPH | Start Date*: 2018-02-09 | |||||||||||
Sponsor Name:MedUni Vienna, Dept of Anesthesia, Critical Care, Div. of Cardiothoracic and Vascular Anesthesia | |||||||||||||
Full Title: Ceftaroline (Zinforo®) as antibiotic prophylaxis for CABG-surgery: An In-vivo microdialysis study | |||||||||||||
Medical condition: Antibiotic prophylaxis for CABG surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005125-12 | Sponsor Protocol Number: LIRALUNG | Start Date*: 2016-05-12 |
Sponsor Name:Dr. Albert Lecube, Ph.D., M.D. | ||
Full Title: MULTICENTRE RANDOMIZED DOUBLE BLIND, CROSSOVER, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFECT OF LIRAGLUTIDE ON LUNG FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (LIRALUNG STUDY) | ||
Medical condition: Type 2 Diabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004782-24 | Sponsor Protocol Number: PRM-151-202 | Start Date*: 2016-03-01 | |||||||||||
Sponsor Name:Promedior, Inc. | |||||||||||||
Full Title: A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF) | |||||||||||||
Medical condition: Idiopathic Pulmonary Fibrosis (IPF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) CZ (Completed) ES (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022863-36 | Sponsor Protocol Number: FIBHGM-ECNC010-2010 | Start Date*: 2013-09-17 | |||||||||||
Sponsor Name:Fundación para la Investigación Biomédica del Hospital | |||||||||||||
Full Title: Phase IV, randomized and controlled study about efficacy an safety of the use of continuous pressure airway CPAP Bussignac in the immediate postoperative period of patients undergoing lung resect... | |||||||||||||
Medical condition: postoperative atelectasis / pneumonias | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001555-14 | Sponsor Protocol Number: NBK272/1/2021 | Start Date*: 2023-01-05 |
Sponsor Name:Medical University of Gdańsk | ||
Full Title: Assessment of the effect of Wharton's jelly mesenchymal stem cell preparation (WJMSCs) in the treatment of fibrotic interstitial lung diseases | ||
Medical condition: fibrotic interstitial lung disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-004794-31 | Sponsor Protocol Number: KIN-1902-2001 | Start Date*: 2022-08-19 | |||||||||||
Sponsor Name:Kinevant Sciences GmbH | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis | |||||||||||||
Medical condition: chronic pulmonary sarcoidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002393-12 | Sponsor Protocol Number: PRODIGE49 | Start Date*: 2016-08-26 | ||||||||||||||||
Sponsor Name:Fédération Francophone de Cancérologie Digestive | ||||||||||||||||||
Full Title: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 and targeted therapy in first-line treatment of metastatic colorectal cancer restricted to the liver | ||||||||||||||||||
Medical condition: | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004088-77 | Sponsor Protocol Number: BA2006/03/03 | Start Date*: 2007-12-03 |
Sponsor Name:BioAlliance Pharma | ||
Full Title: Doxorubicin-Transdrug® in Advanced HepatoCellular Carcinoma A Randomized, Multicenter Phase 2-3 Study. | ||
Medical condition: Advanced hepatocarcinoma (HCC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-003669-17 | Sponsor Protocol Number: NEOPA | Start Date*: 2013-12-17 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma (NEOPA). | |||||||||||||
Medical condition: Non-metastasized, adenocarcinoma of the pancreatic head/uncinate process or body of pancreas that was treated with extended pancreatic head/body resection larger than 2 cm in size (≥cT2) and/or in ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001122-22 | Sponsor Protocol Number: BLUEPAT_FNUSA_2021 | Start Date*: 2021-04-20 | |||||||||||
Sponsor Name:Fakultní nemocnice u sv. Anny v Brně | |||||||||||||
Full Title: Subpleural lung nodules marking with blue dye substance and contrast agent under CT-guided control with subsequent videothoracoscopic wedge resection: prospective randomized study. | |||||||||||||
Medical condition: Focal pulmonary lesions | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000028-33 | Sponsor Protocol Number: D-FR-01070-003 | Start Date*: 2018-07-17 | |||||||||||
Sponsor Name:Ipsen Pharma | |||||||||||||
Full Title: A non-randomised, phase II study to evaluate the optimal uptake time of 68Ga-OPS202 as a sstr2 positive PET imaging agent in subjects with newly diagnosed breast cancer. (Sub-study of Master Protoc... | |||||||||||||
Medical condition: Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001325-31 | Sponsor Protocol Number: NL73551.091.20 | Start Date*: 2020-05-20 | |||||||||||||||||||||
Sponsor Name:Radboud University Medical Center | |||||||||||||||||||||||
Full Title: [68Ga]Ga-DOTA-(RGD)2 PET/CT imaging of activated endothelium in lung parenchyma of COVID-19 patients. | |||||||||||||||||||||||
Medical condition: Maximum 10 patients from the Infectious Diseases ward with proven COVID-19 infection and pulmonary abnormalities on contrast-enhanced CT undergo static PET scans after injection of 70 μg (200 MBq) ... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000149-30 | Sponsor Protocol Number: Edge92882 | Start Date*: 2017-10-25 |
Sponsor Name:University Hospitals of Leicester NHS Trust | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease | ||
Medical condition: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2011-003249-16 | Sponsor Protocol Number: PML_DOC_1102 | Start Date*: 2012-01-06 | |||||||||||
Sponsor Name:University Hospital of Antwerp | |||||||||||||
Full Title: OPEN-LABEL, PROSPECTIVE EXPLORATORY STUDY TO ASSESS THE EFFECTS OF FORMOTEROL AND BECLOMETASONE DIPROPIONATE COMBINATION THERAPY USING A DPI DEVICE ON CENTRAL AND PERIPHERAL AIRWAY DIMENSIONS IN AS... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004244-33 | Sponsor Protocol Number: ATYR1923-C-002 | Start Date*: 2019-10-21 | |||||||||||
Sponsor Name:aTyr Pharma, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients with Pulmonary Sarcoidosis | |||||||||||||
Medical condition: Pulmonary Sarcoidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000417-44 | Sponsor Protocol Number: PHP-OCM-301A | Start Date*: 2016-03-31 | |||||||||||
Sponsor Name:Delcath Systems, Inc | |||||||||||||
Full Title: A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma. | |||||||||||||
Medical condition: Hepatic-Dominant Ocular Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004033-25 | Sponsor Protocol Number: PED-FQ-2016 | Start Date*: 2017-06-19 | ||||||||||||||||
Sponsor Name:Fundació Parc Taulí | ||||||||||||||||||
Full Title: Efect of nebulized bicarbonate on bacterial infections in patients with cystic fibrosis. Randomized clinical trial | ||||||||||||||||||
Medical condition: Cystic Fibrosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001795-15 | Sponsor Protocol Number: COMBAT-19 | Start Date*: 2020-05-07 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: A randomized, double blind, placebo-COntrolled trial of MavrilimumaB for Acute respiratory failure due To COVID-19 pneumonia with hyperinflammation: the COMBAT-19 trial | |||||||||||||
Medical condition: Respiratory failure during COVID-19 pneumonia and hyperinflammation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000614-64 | Sponsor Protocol Number: VIRUSNET201401 | Start Date*: 2015-12-17 | |||||||||||
Sponsor Name:Department of Immunology, Genetics and Pathology (IGP), Rudbeck Laboratory, Uppsala University | |||||||||||||
Full Title: Study of recombinant adenovirus in patients with neuroendocrine neoplasms; safety and efficacy | |||||||||||||
Medical condition: Neuroendocrine neoplasms (NENs) is a heterogeneous group with varying symptoms, tumor biology and treatment response. NENs may occur in any organ, most commonly they are observed in the gastroente... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006441-10 | Sponsor Protocol Number: 116-02 | Start Date*: 2009-06-03 |
Sponsor Name:SCIPHARM SáRL | ||
Full Title: A double blind controlled clinical study to investigate the efficacy and tolerability of subcutaneous Treprostinil sodium in patients with severe non-operable Chronic Thromboembolic Pulmonary Hyper... | ||
Medical condition: Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) CZ (Completed) SK (Completed) DE (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
